Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asy...

ver descrição completa

Detalhes bibliográficos
Autores: Lleó, Alberto, Medrano-Martorell, Santiago, Fortea, Juan
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/53576
Acesso em linha:http://hdl.handle.net/10230/53576
http://dx.doi.org/10.1038/s41467-021-24319-x
Access Level:acceso abierto
Palavra-chave:Alzheimer&apos
s disease
Predictive markers
id ES_eb3a6fa96a4a80608baed34cb228dca1
oai_identifier_str oai:recercat.cat:10230/53576
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
title Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
spellingShingle Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
Lleó, Alberto
Alzheimer&apos
s disease
Predictive markers
title_short Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
title_full Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
title_fullStr Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
title_full_unstemmed Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
title_sort Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome
dc.creator.none.fl_str_mv Lleó, Alberto
Medrano-Martorell, Santiago
Fortea, Juan
author Lleó, Alberto
author_facet Lleó, Alberto
Medrano-Martorell, Santiago
Fortea, Juan
author_role author
author2 Medrano-Martorell, Santiago
Fortea, Juan
author2_role author
author
dc.subject.none.fl_str_mv Alzheimer&apos
s disease
Predictive markers
topic Alzheimer&apos
s disease
Predictive markers
description Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/53576
http://dx.doi.org/10.1038/s41467-021-24319-x
url http://hdl.handle.net/10230/53576
http://dx.doi.org/10.1038/s41467-021-24319-x
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Nat Commun. 2021 Jul 14;12(1):4304
info:eu-repo/grantAgreement/EC/H2020/681712
info:eu-repo/grantAgreement/EC/H2020/860197
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423209408888832
spelling Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndromeLleó, AlbertoMedrano-Martorell, SantiagoFortea, JuanAlzheimer&aposs diseasePredictive markersPlasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.This study was supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126 and PI17/01019 to J.F., PI13/01532 and PI16/01825 to R.B., PI18/00335 to M.C.I., PI18/00435 and INT19/00016 to D.A., PI15/01618 to R.R., PI14/1561 and AC19/00103 to A.L.) and the CIBERNED program (Program 1, Alzheimer Disease to A.L. and SIGNAL study, www.signalstudy.es), partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. This work was also supported by the National Institutes of Health (NIA grants 1R01AG056850 - 01A1; R21AG056974 and R01AG061566 to J.F.), Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT002/16/00408 to A.L.), Fundació La Marató de TV3 (20141210 to J.F., 044412 to R.B. and 201437.10 to R.R.); I. Illán-Gala is supported by the Rio Hortega grant (CM17/00074) from “Acción Estratégica en Salud 2013-2016” and the Global Brain Health Institute (https://www.gbhi.org/). Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas partially supported this work. This work was also supported by Generalitat de Catalunya (SLT006/17/00119 to J.F., SLT006/17/95 to E.V. and SLT006/17/00125 to D.A.) and a grant from the Fundació Bancaria La Caixa to R.B. M.F.I. acknowledges support from the Jérôme Lejeune and Sysley D’Ornano Foundations. A Bejanin was the recipient of a Juan de la Cierva-Incorporación grant from the Spanish Ministry of Economy and Competitiveness (IJCI-2017-32609) and a Miguel Servet I grant (CP20/00038) from the Carlos III Health Institute. T.K.K. holds a research fellowship from the BrightFocus Foundation (#A2020812F) and is further supported by the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson’s Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). The authors would like to thank all the participants with Down’s syndrome, their families and their carers for their support of, and dedication to this research. We also acknowledge the Fundació Catalana Síndrome de Down for global support; Soraya Torres, Shaimaa El Bounasri, Laia Muñoz and Raúl Núñez for laboratory and sample handling; Reyes Alcoverro, Marta Salinas and Tania Martínez for administrative support; Concepción Escola for nursing handling. We also thank the clinicians for their help in acquiring the data reported in this article.Nature Research202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/53576http://dx.doi.org/10.1038/s41467-021-24319-xreponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésNat Commun. 2021 Jul 14;12(1):4304info:eu-repo/grantAgreement/EC/H2020/681712info:eu-repo/grantAgreement/EC/H2020/860197© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/535762026-05-29T05:05:01Z
score 15.812429

Registos relacionados